Werewolf Therapeutics, Inc. (NASDAQ: HOWL) reported Q2 EPS of ($0.40), $0.07 better than the analyst estimate of ($0.47).

For earnings history and earnings-related data on Werewolf Therapeutics, Inc. (HOWL) click here.